Context: Options for chronic treatment of hypoparathyroidism include calcitriol, recombinant human parathyroid hormone, and high-dose vitamin D (D 2 ). D 2 is used in a minority of patients because of fear of prolonged hypercalcemia and renal toxicity. There is a paucity of recent data about D 2 use in hypoparathyroidism.
H ypoparathyroidism is due to the absence or partial deficiency of parathyroid hormone, which leads to hypocalcemia, hyperphosphatemia, and hypercalciuria (1) . The most feared chronic complication of hypoparathyroidism treatment is renal toxicity, manifesting as kidney stone or nephrocalcinosis, followed by renal insufficiency (2) . Additional risks of treatment of hypoparathyroidism include acute episodes of hypercalcemia and hypocalcemia requiring emergency medical treatment (3) . Treatment of hypoparathyroidism remains a challenge and no one treatment has been shown to be satisfactory for every patient (4) . Currently available treatments for hypoparathyroidism include highdose vitamin D (ergocalciferol, D 2 and cholecalciferol, D 3 ), the active metabolite 1,25-dihydroxvitamin D (calcitriol), recombinant human parathyroid hormone, in addition to calcium supplements (5) . In the United States, only D 2 (not D 3 ) is available as a Food and Drug Administration-approved medication, although comparable doses of D 3 (50,000 IU tablets) are available over the counter in some pharmacies and from Internet sources. Calcitriol is the drug used most commonly in the United States for chronic hypoparathyroidism now, with only ;6% treated with D 2 (3) and increasing numbers of patients on human recombinant parathyroid hormone (6) . However, in our clinical experience, D 2 is effective and safe, with most hypoparathyroid patients requiring 50,000 IU per day. However, we are aware of no reports comparing treatment outcome with D 2 vs calcitriol for hypoparathyroidism.
D 2 was the only treatment available for hypoparathyroidism prior to 1933 (7) . At that time, the long halflife of D 2 and potential for prolonged hypercalcemia and renal insufficiency from vitamin D toxicity was one factor that led to the development of dihydrotachysterol (DHT; 1-a-hydroxycholecalciferol), which had a shorter halflife (8) . In 1939, Albright et al. (8) studied three patients with hypoparathyroidism, comparing DHT with D 2 and showed that the ability of the drugs to maintain eucalcemia was similar. They further showed that D 2 caused hypercalcemia only when very high doses, 200,000 to 400,000 IU/d, were used, much higher than doses of D 2 used today for hypoparathyroidism.
In this retrospective study, our goal was to compare renal function and incidents of hypercalcemia and hypocalcemia requiring medical treatment in patients with hypoparathyroidism treated chronically with D 2 (D2 group) vs calcitriol.
Materials and Methods
Patients with hypoparathyroidism who were treated at the University of Maryland Medical Center between 1 January 2003 and 1 January 2013 were identified from billing records (inpatient and outpatient), using the ICD-9 code for hypoparathyroidism, after obtaining Institutional Review Board approval. The diagnosis of chronic hypoparathyroidism was confirmed after review of electronic medical records (by E.A.S., an endocrine fellow and faculty member) in 30 patients, who were included in the study. The following information was extracted from the medical record: age, sex, cause (if known) of hypoparathyroidism, date of diagnosis, history of kidney stones, and serum calcium and creatinine (all available were recorded). Urine calcium levels and renal imaging were recorded, when available. For both creatinine and calcium, only outpatient measures were recorded to avoid transient changes that can be seen in the inpatient setting that would affect the means. For serum creatinine, only the most recent outpatient value was recorded, to avoid spuriously low values by including very old data. For serum calcium, the number of measures available varied among participants, from one (four patients from each group) to 10 (highest number included). The mean and median numbers of serum calcium measures were 5.1/5 in the D2 group and 4.3/4 in the calcitriol group. Only the most recent 2 to 3 years of data were included. Therefore, if a patient had been followed for 16 years (the longest follow-up), only the most recent 3 years of serum calcium data and the most recent serum creatinine values were included in the analysis. Most of the serum creatinine and calcium values were obtained from the electronic medical record (EMR), but in some patients, the laboratory data were only available from paper charts. For all patients who experienced hypocalcemia, data were available from the EMR.
Sixteen patients were treated chronically with vitamin D 2 (D2 group) and 14 with calcitriol (calcitriol group). Fourteen patients in the D2 group and eight patients in the calcitriol group were followed by the authors and other faculty members of the Endocrinology Division at the University of Maryland Medical Center; eight were treated by internal medicine faculty.
Statistical analysis
Fisher's exact test was used to compare data between the D2 and calcitriol groups, because of the small number of participants. Serum calcium levels were corrected for serum albumin: measured calcium 2 [(4 2 measured albumin) 3 0.8] 5 corrected calcium.
Results
The initial list of potential participants received from our billing department contained 155 patient names. Of these, no records were available in our EMR for 52, so these patients were excluded. Of the remaining 104 patients, hypoparathyroidism was the correct diagnosis in 42 (the remaining 60 had primary or secondary hyperparathyroidism or no parathyroid diagnosis). Of the 42 with confirmed hypoparathyroidism, 12 had transient postoperative hypoparathyroidism and were excluded, leaving 30 with chronic hypoparathyroidism. The duration of hypoparathyroidism was at least 4 years in all participants.
Participant clinical characteristics as well as the dose of D 2 or calcitriol used are shown in Table 1 . There were no significant differences in mean age, duration, or etiology of hypoparathyroidism between the two groups. In both groups, most patients were female. The most common etiology of hypoparathyroidism was surgical in both groups, followed by genetic. Most of the patients in D2 group were also taking calcium supplements (400 to 2000 mg of elemental calcium per day). One patient was on calcium carbonate 1000 mg four times a day. In the calcitriol group, half were taking calcium supplements (250 to 2000 mg of elemental calcium per day in all except one patient on 2500 mg three times a day). Table 2 shows clinical outcomes in the D2 and calcitriol groups. There were no significant differences between the calcitriol and D2 groups in mean serum creatinine (0.98 6 0.26 vs 0.92 6 0.33 mg/dL, P = 0.71) or mean corrected (for albumin) serum calcium (8.4 6 0.7 vs 8.6 6 0.6 mg/dL, P = 0.37). Four out of 14 patients in the calcitriol group required emergency treatment [hospitalization or emergency department (ED) visit] for hypocalcemia vs none of the 16 patients in the D2 group (P = 0.03), and three patients in the calcitriol group required multiple hospital visits for hypocalcemia. There were no differences between the calcitriol and D2 groups in the number of hospitalizations and ED visits for hypercalcemia (two in both groups). For the two patients in the D2 group who were hospitalized for hypercalcemia, one patient was on very high-dose D 2 , at 100,000 U twice daily at the time of hospitalization (patient error), and another patient was taking excessive amounts of calcium carbonate in the form of Tums (for indigestion) prior to hospitalization. Information regarding passed kidney stone was not available in one patient in the D2 group and two patients in the calcitriol group. In those with available data, there was no significant difference in incidence of reported passed kidney stone between the two groups: none in the calcitriol group vs one in the D2 group (P = 0.32).
Urine calcium data and renal imaging results were not available for every participant; data available are shown in Table 3 . There was no difference in urine calcium levels for the two groups, and all renal imaging was normal. All serum calcium levels were normal in this figure, even with 25(OH)D levels of 500 ng/mL.
Discussion
Currently only a minority of patients with hypoparathyroidism are treated with ergocalciferol due at least partially to a concern for potential toxicity given its long biological half-life (9) . As a result, calcitriol is the most commonly used treatment, in the United States, with use (12) . Their study included six patients with hypoparathyroidism treated with D 2 doses of 5000 to 100,000 IU/d and showed that serum calcium came to steady-state within 3 months and was unrelated to 25(OH)D level. In five of six hypoparathyroid patients studied, eucalcemia was maintained with 25(OH)D levels up to 500 ng/mL (1250 nmol/L), with no hypercalcemia. The remaining patient remained hypocalcemic in spite of a 25(OH)D level of 548 ng/mL and required a higher D 2 dose than 100,000 IU per day to achieve eucalcemia. This study demonstrated that in hypoparathyroidism, doses of D 2 up to 100,000 IU/d did not cause hypercalcemia and that 25(OH)D levels up to 500 ng/mL did not result in hypercalcemia. However, concern about potential protracted hypercalcemia from D 2 use in hypoparathyroidism has continued to date.
In 1977, Kanis and Russell (13) b Three had computed tomography, two had ultrasound.
c Two had computed tomography, two had ultrasound. concern for potential hypercalcemia and renal toxicity from D 2 treatment of hypoparathyroidism has persisted, and this is one likely reason that D 2 is currently used in a minority of patients with hypoparathyroidism in the United States. Another likely reason is that there is a paucity of recent information available on the use of D 2 in hypoparathyroidism. In a recent study of chronic complications in 120 patients with hypoparathyroidism, the seven patients on D 2 (50,000 to 400,000 IU/d) were said to be eucalcemic, but there was no comparison of complications with those on calcitriol (3). In that study, in the entire study group, 33% required at least one ED visit or hospitalization for hypocalcemia (62%) or hypercalcemia (12%), but no comparison of these complications was made between those treated with calcitriol vs D 2 .
The ability to maintain eucalcemia with D 2 treatment in hypoparathyroidism is most likely possible because at high levels, 25(OH)D is capable of activating the vitamin D receptor, albeit at 0.01 the avidity of 1,25(OH) 2 D (14). It is also possible that at high levels of 25(OH)D, conversion into 1,25(OH) 2 D is possible in the absence of parathyroid hormone, but strong evidence of this is lacking. Although there has been long-term concern that the long half-life of D 2 places hypoparathyroid patients at high risk of hypercalcemia and renal damage, no study has actually shown this to be the case with D 2 doses in the range used today (50,000 to 100,000 IU/d). Additionally, there have been no recent reports comparing outcome in patients treated with D 2 vs calcitriol. Our study, although small, showed no difference in the incidence of hypercalcemia and no difference in serum creatinine in patients treated chronically with D 2 vs calcitriol. Additionally, we found significantly less need for emergency care (hospitalization and ED visits combined) for hypocalcemia in the D2 group vs the calcitriol group. This is not unexpected due to the short half-life of calcitriol. Patients on calcitriol can become symptomatic if they miss 1 day of medication.
The likely explanation for the low rate of hypercalcemia in our D2 group is that the dose of D 2 used by our patients (41,326 6 30,198 IU/d) was far below doses that were shown to cause toxicity (.100,000 IU/d) in earlier studies. For example, in the 1939 study by Albright et al. (8) , the D 2 doses that caused hypercalcemia were 200,000 to 400,000 IU/d. In a 1977 study by Gerter and Domenech (12) , using lower doses of vitamin D 2 or D 3 (5000 to 100,000 IU/d) in 39 patients with metabolic bone disease, including six patients with hypoparathyroidism, the linear relationship between the dose and level of 25(OH) D was shown (12) . Of note, the 25(OH) D level in these patients ranged from 188 to 1250 nmol/L (75 to 500 ng/mL) (12) . The 25(OH)D level was .1250 nmol/L (500 ng/mL) in all patients treated with D 2 or D 3 at doses of $80,000 U/d, and despite these high levels, no significant correlation was found between levels of 25(OH)D and serum calcium (12) . Most patients were eucalcemic over this dose range and none developed serious hypercalcemia. In a more recent study by Schilling and Ziegler (9) in 1997, patients with hypoparathyroidism treated with D 3 required doses of 10,000 to 70,000 IU per day to achieve eucalcemia and had 25(OH)D levels between 100% and 700% of the upper normal value (9) . Although a significant correlation between 25(OH)D and serum calcium was noted in that review, there was great overlap in 25(OH)D levels between eucalcemic and hypocalcemic patients, and therefore a threshold of 25(OH)D needed for eucalcemia could not be determined (9) . It is notable that some hypoparathyroid patients remained hypocalcemic with 25(OH)D levels as high as 400 ng/mL (9) .
Therefore, although there is a linear relationship between dose of D 2 and level of 25(OH)D (9, 12) in hypoparathyroidism, there is a poor correlation between 25(OH)D and serum calcium levels, and thus routine measurement of 25(OH)D is not helpful in dosing D 2 . However, the 25(OH)D level can be used to determine compliance and absorption.
In agreement with the previous studies mentioned earlier, we found a linear correlation between D 2 dose and 25(OH)D in patients with hyhpoparathyroidism, but no correlation between 25(OH)D and serum calcium levels. In our patients with available data, the 25(OH)D level ranged between 121 and 456 ng/mL in the D2 group. Despite these high 25(OH)D levels, hypercalcemia was rare and no different than in those treated with calcitriol. One patient with a 25(OH)D level of 246 ng/mL was hypocalcemic, with a corrected serum calcium of 7.1 mg/dL.
The drug of choice for treatment of acute hypoparathyroidism is calcitriol, because of its rapid onset of action. After stabilization of serum calcium on calcitriol, our practice is to convert patients to D 2 with close monitoring. After starting D 2 (50,000 U/d), we maintain patients on calcitriol for 2 to 3 months, with weekly monitoring of serum calcium and tapering off of calcitriol as D 2 reaches equilibrium (2 to 3 months). The inexpensive cost of D 2 is an advantage for many patients.
Strengths of our study include the long duration of hypoparathyroidism in our patients (all .4 years) and multiple measures of serum calcium and creatinine. Limitations of our study include the small number of patients, the retrospective design, the lack of 24 hour urine calcium measures and renal imaging in all patients, and the lack of evaluation for nephrocalcinosis. However, the important outcomes of clinical kidney stones and levels of serum creatinine were not significantly different between the D2 and calcitriol groups. Another limitation is that we relied on patient report of hospitalization and emergency room visits and medical records from our hospital, and it is possible that some patients may have had hospitalizations or emergency room visits at other hospitals and failed to report this to their physicians.
Conclusions
We found no evidence of higher serum creatinine in patients with hypoparathyroidism who were chronically treated with D 2 compared with calcitriol. Additionally, we observed significantly less morbidity from hypocalcemia in patients who were treated with D 2 compared with calcitriol. A larger study will be needed to confirm our results, ideally a prospective long-term study including systematic urine calcium measures and renal ultrasounds. Treatment with vitamin D 2 should be considered in patients with hypoparathyroidism, particularly in those requiring medical care for repeated episodes of hypocalcemia.
